How Private Equity Is Buying Up Independent Pharmacies

Lucas and Luna explore the rapid consolidation of independent pharmacies by private equity firms, focusing on the case of Clinical Partners, a mid-market PE firm that has acquired over 200 independent pharmacies across the Midwest since 2021. They break down the economics: independent pharmacies are stable cash-flow businesses with a median EBITDA margin of 15-18 percent, but they face unsustainable pressure from pharmacy benefit managers (PBMs). Lucas explains the 'buy-and-build' strategy where PE firms roll up multiple pharmacies to create negotiating power against PBMs like CVS Caremark and Express Scripts. Luna highlights the trade-offs: pharmacists lose clinical autonomy but gain back-office support and better contract terms. The episode also touches on looming regulatory changes, including the PBM Transparency Act of 2025, which could reshape the economics of the roll-up thesis. A must-hear for anyone interested in the intersection of healthcare and private equity. #PrivateEquity #IndependentPharmacies #PharmacyConsolidation #ClinicalPartners #PBMs #BuyAndBuild #Midwest #PharmacyEconomics #EBITDA #HealthcareRollUps #PharmacyBenefitManagers #RegulatoryRisk #PBMTransparencyAct #BusinessStrategy #Finance #BusinessPodcast #FexingoBusiness #PEStrategies Keep every episode free: buymeacoffee.com/fexingo